Anteotech Ltd · ASX:ADO
Anteotech — Anteo Diagnostics — Shareholder Meeting (November 2015)
33 slides from Anteotech's shareholder meeting presentation, Nov 9, 2015
Slide 1: Anteo Diagnostics Limited Annual General Meeting
For personal use only Anteo Diagnostics Limited (ASX:ADO) Annual General Meeting 9 November 2015 NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
Slide 2: Meeting Format
Meeting Format For personal use only 1. Introductions 2. Formal Resolutions 3. CEO Report 4. Other Business 5. Meeting Close 2 NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
Slide 3: Introductions
Introductions For personal use only Anteo Diagnostics Limited – Directors in attendance M M Mark Bouris, Dr Geoff Richard Martin, Sandra Andersen, Dr John Hurrell, Non-Executive Cumming, CEO Executive Non-Executive Non-Executive Chairman Director and CFO Director Director Grant Thornton – Auditor in
Slide 4: Formal Resolutions
Formal Resolutions For personal use only Resolution Description Resolution 1: Adoption of Directors’ Remuneration Report Resolution 2: Re- Election of Director (Ms Sandra Andersen) Resolution 3: Approval of 10% Placement Capacity Resolution 4: Ratification of Share Issue Resolution 5: Approval of Is
Slide 5: Resolutions: Proxy Count
Resolutions: Proxy Count For personal use only Resolution Description For Against Open Excluded Abstain Totals Resolution Adoption of Directors’ 1: Remuneration Report 203,796,011 9,282,883 0 0 670,428 213,749,322 Resolution Re- Election of 2: Director (Ms Sandra 188,360,235 10,549,144 13,928,515 0
Slide 6: CEO Update: the year in review
For personal use only CEO Update: the year in review 6 NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
Slide 7: Forward Looking Statement
Forward Looking Statement For personal use only The purpose of the presentation is to provide an update of the business of Anteo Diagnostics (ASX:ADO). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Ac
Slide 8: Investment Highlights
Investment Highlights For personal use only • Anteo Diagnostics has a unique, disruptive, nanoglue technology that can be used in a variety of applications, supported by a strong IP portfolio • Customers are now working with the Mix&Go technology in IVD, POC, Life Sciences, Bioseparations and Medica
Slide 9: Pursuing Strategic Growth
Pursuing Strategic Growth For personal use only The five growth areas have led Anteo to crystallise our approach to revenue generating activities, and position the Company for future growth. 9 NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
Slide 10: Exploiting Existing IP
Exploiting Existing IP For personal use only 10 NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
Slide 11: Current Accessible Markets for Mix&Go
Current Accessible Markets for Mix&Go For personal use only Primary markets Anteo is heavily focused on driving Market Value (US$ pa) growth in primary markets Global In Vitro Diagnostics Appetite for Mix&Go has reached a 15 billion* (IVD) - immunoassays tipping point with IVD and life-sciences cust
Slide 12: Diagnostics Market Dynamics
Diagnostics Market Dynamics For personal use only Global In Vitro Diagnostics Market (2012) • The global immunoassay market size Total USD 64.7 billion has forecast revenues of US$19.1 billion by 2018 Microbiology Hemostasis • Tier-one players (Roche, et al) control Hematology 5% 3% 7% 80% of market
Slide 13: Anteo's Solution: Mix&Go Universal Glue
Anteo’s Solution: Mix&Go Universal Glue For personal use only 3D structure is Orientation Undamaged, Proprietary solution: damaged is random oriented metal polymers Without Mix&Go With Mix&Go Consequences Characteristics Benefits Vast majority of proteins are non- Undamaged, fully functional protein
Slide 14: Mix&Go Sales Cycle
Mix&Go Sales Cycle For personal use only Mix&Go Product Suite 1 2 3 Direct Sales: Co-Development: Licensing / supply: Distributors include Partners include Partners include Sigma Aldrich, BBI, POC1, IMRA Merck KGaA, Veritas & Koma & Cook Medical Affymetrix & Bangs Biotech Product Customer Market Dis
Slide 15: Adoption of Mix&Go in Core IVD/LS Markets
Adoption of Mix&Go in Core IVD/LS Markets For personal use only o Licensing - (Merck KGaA, Affymetrix, Bangs Laboratories) o Co-development of products through partnerships (BBI, POC1, IMRA, Sigma Aldrich plus a number of global life science and veterinary companies worldwide) o Product sales - Mix&
Slide 16: Exploiting Existing IP
Exploiting Existing IP For personal use only o AMG kits – launch of the Anteo Mix&Go off the shelf products o Kits combine IP with Anteo’s know- how allowing users to adapt quickly to Mix&Go chemistry o The introduction of the 200nm kit has brought a strong response and is part of a regulatory trial
Slide 17: Expanding Core Competencies and IP
Expanding Core Competencies and IP For personal use only 17 NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
Slide 18: Expanding Core Competencies and IP
Expanding Core Competencies and IP For personal use only o Increasing portfolio in nanometre thin glues – for almost any platform and surface (hydrophilic to hydrophobic) o Toolkit that complements Mix&Go (in all AMG products) o Patent portfolio progress - 5 new • Conjugating Molecules to Particles,
Slide 19: Development of Products
Development of Products For personal use only 19 NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
Slide 20: Development of Products
Development of Products For personal use only 3 Mix&Go and 5 AMG Kits on Market o AMG™ Activation Kit for Multiplex Microspheres – December 2014: custom developed for use with Luminex particles o AMG™ Coupling Kit, 200 nm Magnetic Particles - primarily used Above: a selection of products available t
Slide 21: Exploiting Non-core Opportunities
Exploiting Non-core Opportunities For personal use only 21 NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
Slide 22: Exploring Non-core Opportunities
Exploring Non-core Opportunities For personal use only o Cook Medical collaboration – assessing the use of Mix&Go in vivo (in bodies) through medical device applications – good relationship and prototypes well received o Anteo Energy project – Research using Anteo’s nanoglue technology affirms value
Slide 23: Acquisition of Synergistic Assets
Acquisition of Synergistic Assets For personal use only 23 NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
Slide 24: Acquisition of Synergistic Assets: DIAsource
Acquisition of Synergistic Assets: DIAsource For personal use only o Established in 1971, DIASource is a privately- owned and independent specialist diagnostic company, based in Belgium o Vertically-integrated company that develops, manufactures, markets and distributes clinical diagnostic products
Slide 25: DIAsource: Company Overview
DIAsource: Company Overview For personal use only 2 • Located in a 4,500m facility in the science park of the University Louvain-la-Neuve, near Brussels in NETHERLANDS Belgium Louvain-La-Neuve • ISO 13485 manufacturing facility GERMANY that produces FDA/CE approved BELGIUM products with further capa
Slide 26: DIAsource: Key People
DIAsource: Key People For personal use only Rolf Sickman, Chairman • Commenced career at the Amsterdam stock exchange as an advisor for institutional investors on fixed income investments • In 1988, joined Kempen & Co and handled institutional sales fixed income, alternative investments and corporat
Slide 27: DIAsource: Product Categories
DIAsource: Product Categories For personal use only ELISA and Vitamin D assays RIA assays Antibodies Instrumentation Immunoassays Enzyme-linked Radioimmuno- An antibody is a that that test immunosorbent assays (RIA) use protein molecule Vitamin D levels assay (ELISA) is short life that can be found
Slide 28: DIAsource: Global Distribution Platform
DIAsource: Global Distribution Platform For personal use only 66% Sales in EMEA 19% Sales in Americas • Sino FDA approval for Vitamin D 15% Sales in provides large Asia Pacific market opportunity in a d y w rIra China • Additional opportunities for RIA in Republic of Korea – growing market Significa
Slide 29: DIAsource: Revenue & Earnings Growth
DIAsource: Revenue & Earnings Growth For personal use only DIAsource has achieved 4 years of consistent revenue & EBITDA growth – with ongoing margin expansion Earn-out (EO) revenue targets, as agreed with vendors o Generated revenue of €11.9m (A$18.0m) in 2014 and €7.2m (A$10.9m) in the first Margi
Slide 30: DIAsource Acquisition
DIAsource Acquisition For personal use only Anteo Diagnostics to acquire 100% of the equity of DIAsource ImmunoAssays SA in Belgium retaining the operational management. • Purchase price of €15.4m (A$23.3m) with two year vendor earn-out of up to €7.3m (A$11.1m), subject to achievement of revenue and
Slide 31: DIAsource – Key Benefits to Anteo
DIAsource – Key Benefits to Anteo For personal use only DIAsource is a profitable, growing business which will contribute significantly to Anteo's bottom line e Complementary to ADO’s Mix&Go technology - technical synergies ISO 13485 quality accreditation - credibility for Anteo customers – ma
Slide 32: Summary and Conclusions
Summary and Conclusions For personal use only • Anteo’s strong portfolio of nanoglue products and IP positioned within >$60b of addressable market space • Acquisition of DIAsource meets all the criteria set • Cash flow positive business • Technical synergy • Is accretive • Manufacturing capability,
Slide 33: Contacts
For personal use only Contacts Dr Geoff Cumming, CEO Anteo Diagnostics (ASX: ADO) Mobile: +61 417 203 021 Email: geoff.cumming@anteodx.com Web: www.anteodx.com Investor relations: Jane Lowe, IR Department Mobile: +61 411 117 774 Email: jane.lowe@irdepartment.com.au 33 NOT FOR DISTRIBUTION OR RELEASE
Anteo Diagnostics — Shareholder Meeting (November 2015) on 6ix